Cargando…

The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials

BACKGROUND: The evidence base for the widely accepted standard regimen of succinylcholine for rapid sequence induction (1.0 mg kg(− 1)) remains unclear. METHODS: We performed a systematic review and meta-analysis of randomized trials comparing any succinylcholine regimen with the standard regimen (1...

Descripción completa

Detalles Bibliográficos
Autores principales: Putzu, Alessandro, Tramèr, Martin R., Giffa, Maxim, Czarnetzki, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053066/
https://www.ncbi.nlm.nih.gov/pubmed/32122305
http://dx.doi.org/10.1186/s12871-020-00968-1
_version_ 1783502965698461696
author Putzu, Alessandro
Tramèr, Martin R.
Giffa, Maxim
Czarnetzki, Christoph
author_facet Putzu, Alessandro
Tramèr, Martin R.
Giffa, Maxim
Czarnetzki, Christoph
author_sort Putzu, Alessandro
collection PubMed
description BACKGROUND: The evidence base for the widely accepted standard regimen of succinylcholine for rapid sequence induction (1.0 mg kg(− 1)) remains unclear. METHODS: We performed a systematic review and meta-analysis of randomized trials comparing any succinylcholine regimen with the standard regimen (1.0 mg kg(− 1)) and reporting on intubating conditions and/or apnoea times. Results were expressed as absolute risk differences (ARD) for dichotomous data and mean differences (MD) for continuous data. RESULTS: We retrieved six trials with relevant data of 864 patients (ASA 1 or 2, aged 18–65 years, body mass index < 30 kg m(− 2)). Four regimens (0.3, 0.4, 0.5, 0.6 mg kg(− 1)) were compared with 1.0 mg kg(− 1) in at least three trials each, and three (0.8, 1.5, 2 mg kg(− 1)) in one each. With 0.3 to 0.5 mg kg(− 1), the likelihood of excellent intubating conditions was significantly decreased (ARD − 22% to − 67%). With 0.3 and 0.4 mg kg(− 1), but not with 0.5, 0.6, 0.8, 1.5 and 2.0 mg kg(− 1), the likelihood of unacceptable intubating conditions was significantly increased (ARD + 22% and + 32%, respectively). With 2.0 mg kg(− 1), but not with 0.8 or 1.5 mg kg(− 1), the likelihood of excellent intubating conditions was significantly increased (ARD + 23%). Apnoea times were significantly shorter with regimens ≤0.8 mg kg(− 1) (MD − 1.0 to − 3.4 min) but were not reported with 1.5 or 2.0 mg kg(− 1). CONCLUSIONS: With succinylcholine regimens ≤0.5 mg kg(− 1), excellent intubating conditions are less likely and apnoea times are shorter, compared with 1 mg kg(− 1). With 0.3 and 0.4 mg kg(− 1), unacceptable intubating conditions are more common. Succinylcholine 1.5 mg kg(− 1) does not produce more often excellent conditions compared with 1 mg kg(− 1), while 2.0 mg kg(− 1) does, but the database with these regimens is weak and apnoea times remain unknown. Limited information size and strong statistical heterogeneity decrease the certainty of the evidence.
format Online
Article
Text
id pubmed-7053066
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70530662020-03-10 The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials Putzu, Alessandro Tramèr, Martin R. Giffa, Maxim Czarnetzki, Christoph BMC Anesthesiol Research Article BACKGROUND: The evidence base for the widely accepted standard regimen of succinylcholine for rapid sequence induction (1.0 mg kg(− 1)) remains unclear. METHODS: We performed a systematic review and meta-analysis of randomized trials comparing any succinylcholine regimen with the standard regimen (1.0 mg kg(− 1)) and reporting on intubating conditions and/or apnoea times. Results were expressed as absolute risk differences (ARD) for dichotomous data and mean differences (MD) for continuous data. RESULTS: We retrieved six trials with relevant data of 864 patients (ASA 1 or 2, aged 18–65 years, body mass index < 30 kg m(− 2)). Four regimens (0.3, 0.4, 0.5, 0.6 mg kg(− 1)) were compared with 1.0 mg kg(− 1) in at least three trials each, and three (0.8, 1.5, 2 mg kg(− 1)) in one each. With 0.3 to 0.5 mg kg(− 1), the likelihood of excellent intubating conditions was significantly decreased (ARD − 22% to − 67%). With 0.3 and 0.4 mg kg(− 1), but not with 0.5, 0.6, 0.8, 1.5 and 2.0 mg kg(− 1), the likelihood of unacceptable intubating conditions was significantly increased (ARD + 22% and + 32%, respectively). With 2.0 mg kg(− 1), but not with 0.8 or 1.5 mg kg(− 1), the likelihood of excellent intubating conditions was significantly increased (ARD + 23%). Apnoea times were significantly shorter with regimens ≤0.8 mg kg(− 1) (MD − 1.0 to − 3.4 min) but were not reported with 1.5 or 2.0 mg kg(− 1). CONCLUSIONS: With succinylcholine regimens ≤0.5 mg kg(− 1), excellent intubating conditions are less likely and apnoea times are shorter, compared with 1 mg kg(− 1). With 0.3 and 0.4 mg kg(− 1), unacceptable intubating conditions are more common. Succinylcholine 1.5 mg kg(− 1) does not produce more often excellent conditions compared with 1 mg kg(− 1), while 2.0 mg kg(− 1) does, but the database with these regimens is weak and apnoea times remain unknown. Limited information size and strong statistical heterogeneity decrease the certainty of the evidence. BioMed Central 2020-03-02 /pmc/articles/PMC7053066/ /pubmed/32122305 http://dx.doi.org/10.1186/s12871-020-00968-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Putzu, Alessandro
Tramèr, Martin R.
Giffa, Maxim
Czarnetzki, Christoph
The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials
title The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials
title_full The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials
title_fullStr The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials
title_full_unstemmed The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials
title_short The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials
title_sort optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053066/
https://www.ncbi.nlm.nih.gov/pubmed/32122305
http://dx.doi.org/10.1186/s12871-020-00968-1
work_keys_str_mv AT putzualessandro theoptimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials
AT tramermartinr theoptimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials
AT giffamaxim theoptimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials
AT czarnetzkichristoph theoptimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials
AT putzualessandro optimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials
AT tramermartinr optimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials
AT giffamaxim optimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials
AT czarnetzkichristoph optimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials